TACROLIMUS EXTENDED RELEASE CAPSULES
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $961,014 | 64 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $955,194 | 63 | 99.4% |
| Consulting Fee | $5,820 | 1 | 0.6% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody DSA Formation and the Development of Immune Activation IA in de Novo Kidney Transplant Recipients ASTOUND | Astellas Pharma Global Development | $732,085 | 0 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release Astagraf XL in HLA Sensitized Kidney Transplant Recipients | Astellas Pharma Global Development | $113,275 | 0 |
| Once-a-day Tacrolimus Conversion Study The OneTAC Trial | Astellas Pharma Global Development | $67,000 | 0 |
| A Pharmacokinetic analysis of tacrolimus ER dosing in obese kidney transplant recipients | Astellas Pharma Global Development | $42,834 | 0 |
Top Doctors Receiving Payments for TACROLIMUS EXTENDED RELEASE CAPSULES
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $955,194 | 63 |
| , M.D., PH.D | Surgery | Cleveland, OH | $5,820 | 1 |
Manufacturing Companies
- Astellas Pharma Global Development $955,194
- Astellas Pharma Inc $5,820
Product Information
- Type Drug
- Total Payments $961,014
- Total Doctors 1
- Transactions 64
About TACROLIMUS EXTENDED RELEASE CAPSULES
TACROLIMUS EXTENDED RELEASE CAPSULES is a drug associated with $961,014 in payments to 1 healthcare providers, recorded across 64 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2018 to 2018. In 2018, $961,014 was paid across 64 transactions to 1 doctors.
The most common payment nature for TACROLIMUS EXTENDED RELEASE CAPSULES is "Unspecified" ($955,194, 99.4% of total).
TACROLIMUS EXTENDED RELEASE CAPSULES is associated with 4 research studies, including "To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody DSA Formation and the Development of Immune Activation IA in de Novo Kidney Transplant Recipients ASTOUND" ($732,085).